I undersøgelsen med patienter med svær allergisk astma var der ingen forskel mellem Xolair - og pla - cebobehandlede patienter hvad angår hyppigheden af forværring af astma, men Xolair mindskede antallet af forværringer lige så meget som i tidligere undersøgelser.
In the study of patients with severe allergic asthma, although there was no difference in the rate of asthma exacerbations between Xolair- and placebo-treated patients, Xolair led to a reduction in the number of exacerbations that was consistent with previous studies.